Related Experiment Videos
Further reduction in mortality following myocardial infarction
1Cardiology Unit, Solvay Healthcare Ltd, Southampton SO18 3JD.
Hospital Medicine (London, England : 1998)
|November 9, 2002
Abstract:
Omacor is a new omega-3 fatty acid product that is licensed for secondary prevention post-myocardial infarction. It confers an additional 20% reduction in all-cause mortality, based on the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico prevenzione (GISSI-P) study data. The GISSI-P results are compared with other trials of secondary prevention.